Volume 142, Issue 4 , Pages 576.e1-576.e8, October 2006
Baseline Optical Coherence Tomography Predicts the Development of Glaucomatous Change in Glaucoma Suspects
Purpose
To assess whether baseline retinal nerve fiber layer (RNFL) measurements obtained with optical coherence tomography (OCT2; Carl Zeiss Meditec, Dublin, California, USA) are predictive of the development of glaucomatous change.
Design
Cohort study.
Methods
Participants were recruited from the University of California, San Diego (UCSD) longitudinal Diagnostic Innovations in Glaucoma Study (DIGS). One eye was studied from each of 114 glaucoma suspects with normal standard automated perimetry (SAP) and OCT RNFL imaging at baseline. The cohort was divided into two groups based on the development of glaucomatous change (repeatable abnormal visual fields and/or a change in the stereophotographic appearance of the optic disk). Cox proportional hazards models were used to determine the predictive ability of OCT RNFL thickness measurements.
Results
Over a 4.2-year average follow-up period, 23 eyes (20%) developed glaucomatous changes and 91 (80%) did not. At baseline, thinner RNFL measurements, higher SAP pattern standard deviation (PSD), “glaucoma” stereophotograph assessment, and thinner central corneal thickness (CCT) were associated with the study endpoints in univariate analysis. After adjusting for age, intraocular pressure (IOP), CCT, and PSD in multivariate models, a 10 μm thinner average, superior and inferior RNFL at baseline was predictive of glaucomatous change [hazard ratio (95% CI); 1.51 (1.11 to 2.12), 1.57 (1.17 to 2.18), and 1.49, (1.19 to 1.91), respectively]. Results were consistent when stereophotographic assessment was included in multivariate analysis.
Conclusions
Thinner OCT RNFL measurements at baseline were associated with development of glaucomatous change in glaucoma suspect eyes. RNFL thinning was an independent predictor of the glaucomatous change, even when adjusting for stereophotograph assessment, age, IOP, CCT, and PSD.
To access this article, please choose from the options below
Supported in part by NIH Grants EY11008 (LMZ), EY08208 (PAS), and MEC/CAPES grant BEX2230/04-6 (IMT). Participant retention incentive grants in the form of glaucoma medication at no cost: Alcon Laboratories Inc (Fort Worth, Texas), Allergan (Irvine, California), Pfizer Inc (New York, New York), and SANTEN Inc (Napa, California).
PII: S0002-9394(06)00580-0
doi:10.1016/j.ajo.2006.05.004
© 2006 Elsevier Inc. All rights reserved.
Volume 142, Issue 4 , Pages 576.e1-576.e8, October 2006
